Gilead's Shot in the Arm
Morningstar CEO of the Year finalist John Martin's smart capital-allocation decisions have helped drive a 100-fold increase in this biopharmaceutical's stock since he took over in 1996.
Morningstar CEO of the Year finalist John Martin's smart capital-allocation decisions have helped drive a 100-fold increase in this biopharmaceutical's stock since he took over in 1996.
Todd Wenning: One of the key tenants of our stewardship methodology here at Morningstar is capital allocation. And we want to see CEOs that do a very, very good job of allocating capital for the benefit of shareholder value.
Gilead Sciences' (GILD) CEO John Martin has done a fantastic job doing this since 1996. Since he took over the role in that year, the stock is up more than 100-fold. As a result of Gilead's strong capital-allocation strategy, one of the acquisitions that they have made in recent years that has done very, very well for shareholders is the 2012 acquisition of Pharmasset.
Senior analyst Karen Andersen, who covers Gilead full time, thought this was a very strong acquisition. She thinks that the company's return on invested capital could reach the mid-20% range again by 2018. So, we are very excited to have John Martin as a CEO of the Year finalist for 2014.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.